These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 22042222

  • 1. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
    Blache D, Gautier T, Tietge UJ, Lagrost L.
    FASEB J; 2012 Feb; 26(2):927-37. PubMed ID: 22042222
    [Abstract] [Full Text] [Related]

  • 2. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E, Gautier T, Rosengren B, Dikkers A, Behrendt M, Grass DS, Rader DJ, Tietge UJ.
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
    Luchtefeld M, Bandlow N, Tietge UJ, Grote K, Pfeilschifter J, Kaszkin M, Beck S, Drexler H, Schieffer B.
    Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
    [Abstract] [Full Text] [Related]

  • 4. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
    Staprans I, Pan XM, Rapp JH, Feingold KR.
    Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
    [Abstract] [Full Text] [Related]

  • 5. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
    Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P.
    Circulation; 2003 Apr 01; 107(12):1640-6. PubMed ID: 12668499
    [Abstract] [Full Text] [Related]

  • 6. Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia.
    Bai H, Liu BW, Deng ZY, Shen T, Fang DZ, Zhao YH, Liu Y.
    Free Radic Biol Med; 2006 May 15; 40(10):1796-803. PubMed ID: 16678017
    [Abstract] [Full Text] [Related]

  • 7. Intraperitoneal injection of platelet secretory products into mice increases macrophage uptake of oxidized low density lipoprotein.
    Hussein O, Brook GJ, Aviram M.
    Isr J Med Sci; 1993 Aug 15; 29(8):453-9. PubMed ID: 8407271
    [Abstract] [Full Text] [Related]

  • 8. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.
    Circ Res; 2004 Oct 15; 95(8):789-97. PubMed ID: 15388641
    [Abstract] [Full Text] [Related]

  • 9. [Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia].
    Deng Z, Liu B, Zhou J, Zhang Z, Liu Y, Bai H.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct 15; 34(4):704-7. PubMed ID: 14619587
    [Abstract] [Full Text] [Related]

  • 10. Binding of oxidized low-density lipoprotein on circulating platelets is increased in patients with acute coronary syndromes and induces platelet adhesion to vascular wall in vivo--brief report.
    Stellos K, Sauter R, Fahrleitner M, Grimm J, Stakos D, Emschermann F, Panagiota V, Gnerlich S, Perk A, Schönberger T, Bigalke B, Langer HF, Gawaz M.
    Arterioscler Thromb Vasc Biol; 2012 Aug 15; 32(8):2017-20. PubMed ID: 22701021
    [Abstract] [Full Text] [Related]

  • 11. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis.
    Siegel-Axel D, Daub K, Seizer P, Lindemann S, Gawaz M.
    Cardiovasc Res; 2008 Apr 01; 78(1):8-17. PubMed ID: 18218686
    [Abstract] [Full Text] [Related]

  • 12. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
    Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis AJ, Berliner JA.
    Arterioscler Thromb Vasc Biol; 1999 May 01; 19(5):1291-8. PubMed ID: 10323782
    [Abstract] [Full Text] [Related]

  • 13. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA, Amaral ME, Boschero AC, Nunes VS, Harada LM, Castilho LN, Oliveira HC.
    Metabolism; 2001 May 01; 50(5):530-6. PubMed ID: 11319713
    [Abstract] [Full Text] [Related]

  • 14. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
    Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, Trias J.
    J Cardiovasc Pharmacol; 2009 Jan 01; 53(1):60-5. PubMed ID: 19129734
    [Abstract] [Full Text] [Related]

  • 15. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
    Kita T, Yokode M, Ishii K, Kume N, Nagano Y, Arai H, Otani H, Ueda Y, Hara S.
    Clin Exp Pharmacol Physiol Suppl; 1992 Jan 01; 20():37-42. PubMed ID: 1446408
    [Abstract] [Full Text] [Related]

  • 16. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
    Tietge UJ, Pratico D, Ding T, Funk CD, Hildebrand RB, Van Berkel T, Van Eck M.
    J Lipid Res; 2005 Aug 01; 46(8):1604-14. PubMed ID: 15897607
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.
    Calzada C, Véricel E, Colas R, Guillot N, El Khoury G, Drai J, Sassolas A, Peretti N, Ponsin G, Lagarde M, Moulin P.
    FASEB J; 2013 Jul 01; 27(7):2855-61. PubMed ID: 23507868
    [Abstract] [Full Text] [Related]

  • 18. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
    Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, Ikeda M, Notoya M, Kamitani S, Arita H.
    J Biol Chem; 2002 Aug 09; 277(32):29116-24. PubMed ID: 12021277
    [Abstract] [Full Text] [Related]

  • 19. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
    Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K.
    Arterioscler Thromb Vasc Biol; 2003 May 01; 23(5):829-35. PubMed ID: 12649088
    [Abstract] [Full Text] [Related]

  • 20. Effects of hypochlorite-modified low-density and high-density lipoproteins on intracellular Ca2+ and plasma membrane Ca(2+)-ATPase activity of human platelets.
    Zabe M, Feltzer RE, Malle E, Sattler W, Dean WL.
    Cell Calcium; 1999 Dec 01; 26(6):281-7. PubMed ID: 10668566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.